Emesis induced by cisplatin and sulfato-1, sulfato-1,2-diaminocyclohexane platinum in dogs and their antiemetics
Huo, M.L.; Wang, Y.S.; Wang, P.; Xiang, Y.S.; Wang, J.G.
Zhongguo Yao Li Xue Bao 7(2): 182-184
1986
ISSN/ISBN: 0253-9756 PMID: 2946163 Document Number: 285818
Document emailed within 1 workday
Related Documents
Ito, J.; Okada, M.; Abo, T.; Okamoto, Y.; Yamashita, T.; Takahashi, K. 1987: Experimental study on the control of cisplatin-induced emesis in dogs Gan to Kagaku Ryoho. Cancer and ChemoTherapy 14(3 Part 1): 706-710Bhandari, P.; Gupta, Y.K.; Seth, S.D. 1989: BRL 43694, a new 5HT3 receptor antagonist, prevents cisplatin-induced emesis in dogs Methods and Findings in Experimental and Clinical Pharmacology 11(5): 361-363
Hannemann, J.; Baumann, K. 1988: Inhibition of lactate-dehydrogenase by cisplatin and other platinum-compounds: enzyme leakage of LDH is not a suitable method to measure platinum-compound-induced kidney cell damage in vitro Research Communications in Chemical Pathology and Pharmacology 60(3): 371-379
Gylys, J.A.; Doran, K.M.; Buyniski, J.P. 1979: Antagonism of cisplatin induced emesis in the dog Research Communications in Chemical Pathology and Pharmacology 23(1): 61-68
Li, Y.T.; Mau, Y.K.; Hsu, K.P. 1991: Control of cisplatin-induced delayed emesis Zhonghua Yi Xue Za Zhi 48(6): 451-455
Roila, F.; Ballatori, E.; Del Favero, A. 1999: Prevention of cisplatin-induced emesis by a neurokinin-1-receptor antagonist New England Journal of Medicine 340(24): 1926-1928
Roila, F.; Tonato, M.; Ballatori, E.; Del Favero, A. 1992: Prevention of cisplatin-induced emesis. The Italian Group for Antiemetic Research Lancet 340(8825): 972
Voravud, N.; Suwanrusmee, H. 2000: Phase II trial of tropisetron and dexamethasone in the prevention of cisplatin-induced emesis Journal of the Medical Association of Thailand 83(6): 668-675
Agostinucci, W.A.; Gannon, R.H.; Golub, G.R.; Martin, R.S.; Schauer, P.K.; Dinonno, E.B. 1988: Continuous i.v. infusion versus multiple bolus doses of metoclopramide for prevention of cisplatin-induced emesis Clinical Pharmacy 7(6): 454-457
Leopold, W.R.; Batzinger, R.P.; Miller, E.C.; Miller, J.A.; Earhart, R.H. 1981: Mutagenicity, tumorigenicity, and electrophilic reactivity of the stereoisomeric platinum(II) complexes of 1,2-diaminocyclohexane Cancer Research 41(11 Part 1): 4368-4377
Cupissol, D.R.; Serrou, B.; Caubel, M. 1990: The efficacy of granisetron as a prophylactic anti-emetic and intervention agent in high-dose cisplatin-induced emesis European Journal of Cancer 26(Suppl 1): S23-S27
Schwartz, P.; Meischen, S.J.; Gale, G.R.; Atkins, L.M.; Smith, A.B.; Walker, E.M. 1977: Preparation and antitumor evaluation of water-soluble derivatives of dichloro(1,2-diaminocyclohexane)platinum(II) Cancer Treatment Reports 61(8): 1519-1525
Tantipalakorn, C.; Srisomboon, J.; Thienthong, H.; Pantusart, A.; Suprasert, P.; Saereesongkhun, C.; Eamtang, S.; Sutthichat, A.; Pautad, N. 2004: Comparison of oral versus intravenous ramosetron in prevention of acute cisplatin-induced emesis: a randomized controlled trial Journal of the Medical Association of Thailand 87(2): 119-125
Hacker, M.P.; Khokhar, A.R.; Krakoff, I.H.; Brown, D.B.; McCormack, J.J. 1986: Water-soluble N-substituted iminodiacetato(1,2-diaminocyclohexane)-platinum(II) complexes as potential antitumor agents Cancer Research 46(12 Part 1): 6250-6254
Garcia-del-Muro, X.; Vadell, C.; Pérez Manga, G.; Bover, I.; Rifá, J.; Beltrán, M.; Barros, M.M.; Germá, J.R.; Fabregat, X.; Moreno, V.; Salvador, A.; Viladiu, P. 1998: Randomised double-blind study comparing tropisetron alone and in combination with dexamethasone in the prevention of acute and delayed cisplatin-induced emesis European Journal of Cancer 34(1): 193-195
Hellenbrecht, D.; Saller, R. 1986: Dose-response relationships of the objective and subjective antiemetic effects and of different side effects of metoclopramide against cisplatin induced emesis Arzneimittel-Forschung 36(12): 1845-1849
Johnson, S.W.; Swiggard, P.A.; Handel, L.M.; Brennan, J.M.; Godwin, A.K.; Ozols, R.F.; Hamilton, T.C. 1994: Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells Cancer Research 54(22): 5911-5916
Fichtinger-Schepman, A.M.; Vendrik, C.P.; van Dijk-Knijnenburg, W.C.; de Jong, W.H.; van der Minnen, A.C.; Claessen, A.M.; van der Velde-Visser, S.D.; de Groot, G.; Wubs, K.L.; Steerenberg, P.A. 1989: Platinum concentrations and DNA adduct levels in tumors and organs of cisplatin-treated LOU/M rats inoculated with cisplatin-sensitive or -resistant immunoglobulin M immunocytoma Cancer Research 49(11): 2862-2867
Manusirivithaya, S.; Chareoniam, V.; Isariyodom, P.; Sungsab, D. 2001: Comparison of ondansetron-dexamethasone-lorazepam versus metoclopramide-dexamethasone-lorazepam in the control of cisplatin induced emesis Journal of the Medical Association of Thailand 84(7): 966-972
Heron, J.F. 1995: Single-agent oral granisetron for the prevention of acute cisplatin-induced emesis: a double-blind, randomized comparison with granisetron plus dexamethasone and high-dose metoclopramide plus dexamethasone Seminars in Oncology 22(4 Suppl. 10): 24-30